Serge Saxonov, Chief Executive Officer and Director of 10x Genomics, Inc. (NASDAQ:TXG), filed a Form 4 on September 3, 2026, reporting a change in beneficial ownership of Class A Common Stock with a transaction dated September 1, 2026.

Key Highlights

  • Transaction code G: Saxonov disposed of 100 shares of Class A Common Stock on September 1, 2026, at a price of $0, coded as a gift (transaction code G).
  • Direct holdings after transaction: Saxonov directly holds 1,075,249 shares of Class A Common Stock following the reported transaction.
  • Andromeda Trust: 27 shares are held indirectly through the Andromeda Trust, for which Saxonov serves as trustee.
  • Y/S Descendants' Trust: 213,250 shares are held indirectly through the Y/S Descendants' Trust, for which Saxonov serves as trustee.
  • Y/S Pot Trust: 71,644 shares are held indirectly through the Y/S Pot Trust, for which Saxonov serves as trustee.

Saxonov's Class A Common Stock Holdings After September 1, 2026 Transaction

According to the filing, Saxonov disposed of 100 shares of Class A Common Stock on September 1, 2026, via transaction code G at a price of $0. Transaction code G denotes a gift under SEC reporting conventions. Following this transaction, the filing reports that Saxonov directly holds 1,075,249 shares of Class A Common Stock.

In addition to his direct holdings, the filing discloses three categories of indirect beneficial ownership. First, 27 shares are held by the Andromeda Trust, for which Saxonov serves as trustee. Second, 213,250 shares are held by the Y/S Descendants' Trust, for which Saxonov also serves as trustee. Third, 71,644 shares are held by the Y/S Pot Trust, for which Saxonov again serves as trustee. No derivative securities were reported in Table II of the filing.

The Form 4 was signed by Randy Wu as Attorney-in-Fact for Serge Saxonov and filed on September 3, 2026. The filing identifies Saxonov's relationship to 10x Genomics, Inc. as both Director and Officer, with the title of Chief Executive Officer.

What Was Disclosed

The filing reports a disposition of 100 shares of Class A Common Stock by Saxonov at $0 via a gift transaction on September 1, 2026, along with his total direct and indirect beneficial ownership positions in 10x Genomics, Inc. following that transaction.